Comprehensive update identifies new MAO inhibitors for fibromyalgia, neuropathic pain, and Alzheimer's disease, suggesting broad therapeutic uses.
Recently patented MAO inhibitors show notable properties, including significant isoform selectivity and therapeutic potential toward other diseases, such as fibromyalgia, CDKL5-deficient disorder, neuropathic pain, and Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Shaldam et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: